 |
- Condition: Alzheimer Disease
Interventions: Drug: S-equol; Other: Placebo
Sponsors: Russell Swerdlow, MD; Ausio Pharmaceuticals, LLC
Recruiting - verified June 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Crenezumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified June 2017 - Condition: Alzheimer's Disease
Interventions: Drug: elenbecestat (E2609); Drug: Placebo
Sponsors: Eisai Co., Ltd.; Biogen
Recruiting - verified March 2017 - Condition: Irregular Sleep-Wake Rhythm Disorder
Interventions: Drug: Lemborexant 2.5 mg; Drug: Lemborexant 5 mg; Drug: Lemborexant 10 mg; Drug: Lemborexant 15 mg; Drug: Lemborexant-matched placebo
Sponsors: Eisai Inc.; Purdue Pharma LP
Recruiting - verified June 2017 - Condition: Alzheimer's Disease
Interventions: Drug: elenbecestat (E2609); Drug: Placebo
Sponsors: Eisai Co., Ltd.; Biogen
Recruiting - verified March 2017 - Conditions: Alzheimer Disease; Mild Cognitive Impairment
Intervention: Drug: Florbetapir F 18 PET Scan
Sponsor: Eli Lilly and Company
Recruiting - verified June 2017 - Conditions: Alzheimer's Disease; Cognitive Impairment
Intervention: Other: Mediterranean Diet
Sponsors: University of Kansas Medical Center; National Institute on Aging (NIA)
Recruiting - verified December 2016 - Conditions: Cognitively Normal Older Adults; Hypertension; Subjective Cognitive Decline; Family History of Alzheimer's Disease
Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine); Behavioral: Aerobic Exercise Training; Other: Usual Care; Behavioral: Stretching Exercise; Drug: Atorvastatin
Sponsors: University of Texas Southwestern Medical Center; Texas Health Resources; University of Kansas Medical Center; Washington University School of Medicine; Pennington Biomedical Research Center; Michigan State University
Recruiting - verified April 2017 - Conditions: Alzheimer Disease; Cognition Disorders
Intervention: Drug: florbetapir F 18 PET scan
Sponsors: Avid Radiopharmaceuticals; Eli Lilly and Company; PRA Health Sciences
Recruiting - verified July 2017 - Condition: Alzheimer's Disease
Interventions: Drug: ABBV-8E12; Drug: placebo for ABBV-8E12
Sponsor: AbbVie
Recruiting - verified May 2017 - Condition: Mild Cognitive Impairment
Interventions: Device: Jawbone Up; Behavioral: Physical Activity Education; Device: ActivPAL
Sponsor: University of Kansas Medical Center
Recruiting - verified August 2016 - Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease (AD)
Intervention:
Sponsors: University of Southern California; Northern California Institute of Research and Education; National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute
Recruiting - verified July 2017 - Condition: Alzheimer's Disease
Interventions: Drug: LY3202626; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified July 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Lanabecestat; Drug: Placebo
Sponsors: Eli Lilly and Company; AstraZeneca
Recruiting - verified June 2017 - Conditions: Dementia With Lewy Bodies; REM Sleep Behavior Disorder; Parkinson's Disease Dementia
Interventions: Drug: Nelotanserin; Drug: Placebo
Sponsor: Axovant Sciences Ltd.
Recruiting - verified June 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Crenezumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified June 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Piromelatine; Drug: Placebo
Sponsor: Neurim Pharmaceuticals Ltd.
Recruiting - verified March 2017 - Condition: Alzheimer's Disease (AD)
Intervention: Drug: Oxaloacetate (OAA)
Sponsor: Russell Swerdlow, MD
Recruiting - verified November 2016 - Condition: Asymptomatic Amyloid-positive
Interventions: Drug: JNJ-54861911, 5 mg; Drug: JNJ-54861911, 25 mg; Drug: Placebo
Sponsor: Janssen Research & Development, LLC
Recruiting - verified June 2017 - Condition: Alzheimer Disease
Intervention:
Sponsor: Banner Health
Recruiting - verified November 2016 - Condition: Alzheimer's Disease
Interventions: Biological: CAD106 Immunotherapy; Other: Placebo to CAD106; Drug: CNP520; Other: Placebo to CNP520
Sponsors: Novartis Pharmaceuticals; Banner Alzheimer's Institute; National Institute on Aging (NIA); Alzheimer's Association; Amgen
Recruiting - verified July 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037); Drug: Aducanumab (BIIB037); Drug: Placebo
Sponsor: Biogen
Recruiting - verified July 2017 - Condition: Alzheimer's Disease
Interventions: Drug: Aducanumab (BIIB037); Drug: Aducanumab (BIIB037); Drug: Placebo
Sponsor: Biogen
Recruiting - verified July 2017 - Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Intervention: Drug: AVP-786
Sponsor: Avanir Pharmaceuticals
Recruiting - verified April 2017 - Condition: Agitation in Patients With Dementia of the Alzheimer's Type
Interventions: Drug: AVP-786; Drug: Placebo
Sponsor: Avanir Pharmaceuticals
Recruiting - verified April 2017 - Condition: Alzheimer's Disease
Interventions: Other: Aerobic Exercise; Other: Standard of Care
Sponsors: University of Kansas Medical Center; National Institute on Aging (NIA)
Recruiting - verified November 2016 - Condition: Cognition Disorders
Interventions: Drug: Solanezumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Alzheimer's Therapeutic Research Institute
Recruiting - verified March 2017
Clinical Trial Locations